Estrogen receptors: Ligand discrimination and antiestrogen action

Benita S Katzenellenbogen, Henry Fang, B. Avery Ince, Farzad Pakdel, Joseph C. Reese, Cynthia H. Wooge, Carol K. Wrenn

Research output: Contribution to journalArticle

Abstract

We have used affinity labeling, site-directed mutagenesis and regional chemical mutagenesis in order to determine regions of the estrogen receptor (ER) important in hormone binding, ligand discrimination between estrogens and antiestrogens, and transcriptional activation. Affinity labelling studies with the antiestrogen, tamoxifen aziridine and the estrogen, ketononestrol aziridine have identified cysteine 530 in the ER hormone binding domain as the primary site of labeling. In the absence of a cysteine at 530 (i.e. Cys530A1a mutant), C381 becomes the site of estrogen-competible tamoxifen aziridine labeling. Hence these two residues, although far apart in the primary linear sequence of the ER protein, must be close in the three-dimensional structure of the protein, in the ER ligand binding pocket, so that the ligand can reach either site. Site-directed and region-specific chemical mutagenesis have identified a region around C530 important in discrimination between estrogens and antiestrogens, and other mutants have allowed identification of residues important in hormone-dependent transcriptional activation. Some transcriptionally inactive ER mutants also function as potent dominant negative ERs, suppressing the activity of wild-type ERs at low concentrations. These studies are beginning to provide a more detailed picture of the ER hormone binding domain and amino acids important in ligand binding and discrimination between different categories of agonist and antagonist ligands. Such information will be important in the design of maximally effective antiestrogens. In addition, since there is now substantial evidence for a mixture of wild-type and variant ERs in breast cancers, our studies should provide insight about the bioactivities of these variant receptors and their roles in modulating the activity of wild type ER, and should lead to a better understanding of the possible role of variant receptors in altered response or resistance to antiestrogen and endocrine therapy in breast cancer.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalBreast Cancer Research and Treatment
Volume27
Issue number1-2
DOIs
StatePublished - Jan 1 1993

Fingerprint

Estrogen Receptor Modulators
Estrogen Receptors
Ligands
Estrogens
Hormones
Mutagenesis
Transcriptional Activation
Cysteine
Breast Neoplasms
Site-Directed Mutagenesis
Amino Acids

Keywords

  • antiestrogens
  • breast cancer
  • estrogen binding
  • estrogen receptors
  • tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Katzenellenbogen, B. S., Fang, H., Ince, B. A., Pakdel, F., Reese, J. C., Wooge, C. H., & Wrenn, C. K. (1993). Estrogen receptors: Ligand discrimination and antiestrogen action. Breast Cancer Research and Treatment, 27(1-2), 17-26. https://doi.org/10.1007/BF00683190

Estrogen receptors : Ligand discrimination and antiestrogen action. / Katzenellenbogen, Benita S; Fang, Henry; Ince, B. Avery; Pakdel, Farzad; Reese, Joseph C.; Wooge, Cynthia H.; Wrenn, Carol K.

In: Breast Cancer Research and Treatment, Vol. 27, No. 1-2, 01.01.1993, p. 17-26.

Research output: Contribution to journalArticle

Katzenellenbogen, BS, Fang, H, Ince, BA, Pakdel, F, Reese, JC, Wooge, CH & Wrenn, CK 1993, 'Estrogen receptors: Ligand discrimination and antiestrogen action', Breast Cancer Research and Treatment, vol. 27, no. 1-2, pp. 17-26. https://doi.org/10.1007/BF00683190
Katzenellenbogen, Benita S ; Fang, Henry ; Ince, B. Avery ; Pakdel, Farzad ; Reese, Joseph C. ; Wooge, Cynthia H. ; Wrenn, Carol K. / Estrogen receptors : Ligand discrimination and antiestrogen action. In: Breast Cancer Research and Treatment. 1993 ; Vol. 27, No. 1-2. pp. 17-26.
@article{d9dd7bcbe2024ecbab21c129fece235c,
title = "Estrogen receptors: Ligand discrimination and antiestrogen action",
abstract = "We have used affinity labeling, site-directed mutagenesis and regional chemical mutagenesis in order to determine regions of the estrogen receptor (ER) important in hormone binding, ligand discrimination between estrogens and antiestrogens, and transcriptional activation. Affinity labelling studies with the antiestrogen, tamoxifen aziridine and the estrogen, ketononestrol aziridine have identified cysteine 530 in the ER hormone binding domain as the primary site of labeling. In the absence of a cysteine at 530 (i.e. Cys530A1a mutant), C381 becomes the site of estrogen-competible tamoxifen aziridine labeling. Hence these two residues, although far apart in the primary linear sequence of the ER protein, must be close in the three-dimensional structure of the protein, in the ER ligand binding pocket, so that the ligand can reach either site. Site-directed and region-specific chemical mutagenesis have identified a region around C530 important in discrimination between estrogens and antiestrogens, and other mutants have allowed identification of residues important in hormone-dependent transcriptional activation. Some transcriptionally inactive ER mutants also function as potent dominant negative ERs, suppressing the activity of wild-type ERs at low concentrations. These studies are beginning to provide a more detailed picture of the ER hormone binding domain and amino acids important in ligand binding and discrimination between different categories of agonist and antagonist ligands. Such information will be important in the design of maximally effective antiestrogens. In addition, since there is now substantial evidence for a mixture of wild-type and variant ERs in breast cancers, our studies should provide insight about the bioactivities of these variant receptors and their roles in modulating the activity of wild type ER, and should lead to a better understanding of the possible role of variant receptors in altered response or resistance to antiestrogen and endocrine therapy in breast cancer.",
keywords = "antiestrogens, breast cancer, estrogen binding, estrogen receptors, tamoxifen",
author = "Katzenellenbogen, {Benita S} and Henry Fang and Ince, {B. Avery} and Farzad Pakdel and Reese, {Joseph C.} and Wooge, {Cynthia H.} and Wrenn, {Carol K.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1007/BF00683190",
language = "English (US)",
volume = "27",
pages = "17--26",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1-2",

}

TY - JOUR

T1 - Estrogen receptors

T2 - Ligand discrimination and antiestrogen action

AU - Katzenellenbogen, Benita S

AU - Fang, Henry

AU - Ince, B. Avery

AU - Pakdel, Farzad

AU - Reese, Joseph C.

AU - Wooge, Cynthia H.

AU - Wrenn, Carol K.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - We have used affinity labeling, site-directed mutagenesis and regional chemical mutagenesis in order to determine regions of the estrogen receptor (ER) important in hormone binding, ligand discrimination between estrogens and antiestrogens, and transcriptional activation. Affinity labelling studies with the antiestrogen, tamoxifen aziridine and the estrogen, ketononestrol aziridine have identified cysteine 530 in the ER hormone binding domain as the primary site of labeling. In the absence of a cysteine at 530 (i.e. Cys530A1a mutant), C381 becomes the site of estrogen-competible tamoxifen aziridine labeling. Hence these two residues, although far apart in the primary linear sequence of the ER protein, must be close in the three-dimensional structure of the protein, in the ER ligand binding pocket, so that the ligand can reach either site. Site-directed and region-specific chemical mutagenesis have identified a region around C530 important in discrimination between estrogens and antiestrogens, and other mutants have allowed identification of residues important in hormone-dependent transcriptional activation. Some transcriptionally inactive ER mutants also function as potent dominant negative ERs, suppressing the activity of wild-type ERs at low concentrations. These studies are beginning to provide a more detailed picture of the ER hormone binding domain and amino acids important in ligand binding and discrimination between different categories of agonist and antagonist ligands. Such information will be important in the design of maximally effective antiestrogens. In addition, since there is now substantial evidence for a mixture of wild-type and variant ERs in breast cancers, our studies should provide insight about the bioactivities of these variant receptors and their roles in modulating the activity of wild type ER, and should lead to a better understanding of the possible role of variant receptors in altered response or resistance to antiestrogen and endocrine therapy in breast cancer.

AB - We have used affinity labeling, site-directed mutagenesis and regional chemical mutagenesis in order to determine regions of the estrogen receptor (ER) important in hormone binding, ligand discrimination between estrogens and antiestrogens, and transcriptional activation. Affinity labelling studies with the antiestrogen, tamoxifen aziridine and the estrogen, ketononestrol aziridine have identified cysteine 530 in the ER hormone binding domain as the primary site of labeling. In the absence of a cysteine at 530 (i.e. Cys530A1a mutant), C381 becomes the site of estrogen-competible tamoxifen aziridine labeling. Hence these two residues, although far apart in the primary linear sequence of the ER protein, must be close in the three-dimensional structure of the protein, in the ER ligand binding pocket, so that the ligand can reach either site. Site-directed and region-specific chemical mutagenesis have identified a region around C530 important in discrimination between estrogens and antiestrogens, and other mutants have allowed identification of residues important in hormone-dependent transcriptional activation. Some transcriptionally inactive ER mutants also function as potent dominant negative ERs, suppressing the activity of wild-type ERs at low concentrations. These studies are beginning to provide a more detailed picture of the ER hormone binding domain and amino acids important in ligand binding and discrimination between different categories of agonist and antagonist ligands. Such information will be important in the design of maximally effective antiestrogens. In addition, since there is now substantial evidence for a mixture of wild-type and variant ERs in breast cancers, our studies should provide insight about the bioactivities of these variant receptors and their roles in modulating the activity of wild type ER, and should lead to a better understanding of the possible role of variant receptors in altered response or resistance to antiestrogen and endocrine therapy in breast cancer.

KW - antiestrogens

KW - breast cancer

KW - estrogen binding

KW - estrogen receptors

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0027517906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027517906&partnerID=8YFLogxK

U2 - 10.1007/BF00683190

DO - 10.1007/BF00683190

M3 - Article

C2 - 8260727

AN - SCOPUS:0027517906

VL - 27

SP - 17

EP - 26

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1-2

ER -